To explore this hypothesis therapeutically, we investigated how idiopathic dystonia and obsessive-compulsive disorder (OCD) respond to a novel dopaminergic treatment using low-dose L-DOPA combined with chlorpromazine (CPZ), which can primarily enhance striosomal D1 dopamine receptor (D1R) signaling in humans. Here, DRD1 is linked to obsessive-compulsive disorder.